Read More Pharma Industry News EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field. byVenkateshJanuary 9, 2026